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Abstract
Cytokines are low molecular weight proteins having roles in essential biological pro-
cesses, particularly for the immune system. As they have a key role to play, an abnormal-
ity in their function can lead to wide variety of diseases (clinical consequences). Thus 
using the cytokines as therapeutic targets has been an area of active research. Of the 
entire family, we would like to shed light on two major ones IL-10 and IL-12 having an 
array of roles in cellular response to infection and autoimmunity. IL-12 is a pro-inflam-
matory cytokine that has been shown to enhance IFN-γ producing T cell responses and 
has been widely tested as a vaccine adjuvant. Many studies have shown that IL-12 acts as 
a link between innate and adaptive immunity by inducing IFN-γ production and polar-
izing naive CD4 T cells to become Th1 cells. It also has roles in CD8 T cell differentiation. 
On the other hand, IL-10 is an anti-inflammatory cytokine and has role in maturation 
of memory CD8 T-cell. It also plays a critical role in preventing autoimmunity and also 
limits tissue injury by interfering with the intensity and duration of immune response. 
We would thus like to discuss in details about the therapeutic use of these cytokines for 
infections as well as diseases such as cancer, autoimmune disorders etc.
Keywords: cytokines, therapy, IL-10, IL-12, inflammation, anti-tumor activity, 
autoimmunity
1. Introduction
Cytokines have an array of roles in immune system. They are involved in regulation of most 
immune responses. They comprise of a large family of low molecular weight proteins play 
essential role in biological processes. They are cellular hormones which mediate cell to cell 
communication. It comprises of interleukins, interferons, chemokines, monokines and lym-
phokines. They are basically involved in signaling pathways and regulating the downstream 
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events. Cytokines are being studied thoroughly from past 3 decades due to the variety of roles 
they play in various infections, diseases etc. They have prominent roles to play when it comes 
to immunity, inflammation, repair and migration [1]. The idea of using them as therapeutics 
is as old as more than 20 years. It evolves from two very different strategies, the first one 
being administration of recombinant purified versions of cytokines and the second in which 
therapeutics are designed against them inhibiting their harmful effects and limiting exces-
sive upregulation. Interferons and CSF (colony stimulating factor) are the ones which form 
the success stories as therapeutics. Their major role seems to be in maintaining the Th1-Th2 
paradigm [2, 3].
The basic classes of cytokines fall under the category of pro-inflammatory, promoting inflam-
mation and anti-inflammatory, resolving inflammation. As the name suggest, the functions 
are opposing and hence a very fine line separates the two, striking a balance is thus extremely 
important. A slight dysregulation can lead to immunopathology, at times fatal to the host. 
Immune homeostasis is attributed via signaling through these small molecules. Thus they 
are prone to dysregulation by any microbial invasion or injury. Micro-organisms have found 
ways to fool the immune system and leading to imbalance in various regulatory pathways.
IL-10 and IL-12 have opposing roles. Owing to their pleotropic properties, they have been 
widely considered for therapy. Various viral infections, tumor models and autoimmune dis-
eases are being targeted through them. Most prominent issue in translating all therapeutic 
approaches to clinic is their opposite effects. Since they are not constitutively expressed, per-
fect timing and cellular location are of paramount importance in designing the right class of 
therapeutics. Here we attempt to shed light on their roles in immune responses and the way 
of their use in therapy. A deeper understanding of their functions, mode of action, involve-
ment of other cytokines, and link between cellular processes would serve as a key feature in 
developing successful modalities.
2. IL-10: structural features
IL-10 family of cytokines falls under the umbrella of class II cytokine family. IL-10 is known 
to limit the overt inflammation preventing tissue damage and acts mainly upon leucocytes. 
It has a major role in maintaining tissue homeostasis. IL-10 was first identified in 1989. It 
was described as a protein involved in inhibition of IFN-γ secretion from Th2 type cells. 
IL-10 is expressed by almost all immune cells, both of innate and adaptive immune system. 
It is expressed by dendritic cells (DCs), macrophages, NK cells, mast cells, T cells and B 
cells etc. [4–8]. Recent evidences suggest that it is also secreted by regulatory T cells (Tregs). 
Structurally it has a stretch of 160 amino acids forming non-covalently linked homodimers. It 
binds to R1 and R2 receptor chains. R1 is shown to have structural similarity with IFNR. IL-10 
functions via activating the JAK-STAT signaling pathway, STAT3 being the downstream tran-
scription factor involved [4, 9]. Various studies have shown that immune cells such as macro-
phages lacking STAT3 escape the suppressive effects of IL-10 on pro-inflammatory cytokine 
production.
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2.1. IL-10 secretion
Besides immune cells several non-immune cells also secrete IL-10. Leucocytes, as well as epi-
thelial cells both falling under different categories of cell types, secrete this anti-inflammatory 
cytokine highlighting its important and major role in homeostasis [10]. Initially, only Th2 type 
T cells were known to secrete IL-10, but more recently Th1, Th9, Th22, CD8 T cells and even 
regulatory T cells have been reported to secrete IL-10 [5, 6]. Pathogen induced IL-10 produc-
tion occurs mainly in APCs such as DC’s and macrophages [11, 12]. TLRs have a major role to 
play in pathogen induced secretion. Pathogen Associated Molecular Patterns (PAMPs) act as 
TLR ligands for the receptors. This in turn initiates a signaling cascade termed as the TLR sig-
naling pathway. Signaling through TIR domain conjugated to adapter molecules, either TRIFF 
or MyD88 leads to IL-10 secretion and other cytokines [13]. TLR 2 ligand has been studied 
extensively and is considered as a major inducer of macrophage derived IL-10. Macrophages 
are the only cells also producing IL-10 via the TLR3 signaling pathway [14, 15]. LPS is also an 
inducer of IL-10 via common TRIF and MyD88 signaling via type I IFNs. Signaling through 
the MyD88 leads to activation of NF-κβ and MAPK activation. MAPK functions via ERK 
group of kinases. The differential levels of IL-10 secreted/expressed are dependent upon ERK 
activation strength in DC’s and macrophages. Signaling via this route is often exploited for 
finding new targets of anti-inflammatory drugs. Regulatory T cells (Tregs) are very recent 
and major producers of IL-10. Tregs are characterized by expression of transcription factor 
Foxhead box P3 (FOXP3). Tregs must receive in-vivo signals to induce IL-10 expression. A 
proper understanding through these cell types however remains elusive.
2.2. Regulation of immune responses through IL-10
Microbial sensing through the innate immune system initiates a signaling cascade termi-
nating into generation of pro-inflammatory cytokines. This creates an inflammatory envi-
ronment favorable for the activation of adaptive immune cells, however higher levels of 
inflammation can give rise to systemic and metabolic imbalances having deleterious effects 
to the host. Therefore the immune system has developed anti-inflammatory mechanisms to 
limit the production of pro-inflammatory molecules thus limiting tissue damage and main-
taining a state of homeostasis. Interleukin 10 (IL-10) is a potent anti-inflammatory cytokine 
that plays a crucial and essential role in averting inflammatory and autoimmune patholo-
gies. It has also role in limiting antiviral, antibacterial responses, remodeling damaged tissues 
and wound healing. Deficiency or aberrant expression of IL-10 can enhance inflammatory 
response to microbial challenge but also lead to development of inflammatory bowel disease 
and a number of autoimmune diseases. Mice studies have shown that IL-10 deficiency leads 
to exacerbate immune responses to microbial or bacterial challenge. Thus, impaired IL-10 
expression or signaling can enhance clearance of pathogens during an acute infection leading 
to exaggerated inflammatory responses, ultimately leading to immunopathology and tissue 
damage. Conversely, some pathogens can harness the immunosuppressive capacity of IL-10 
to limit host immune response, leading to persistent infection characterized by unaffected 
pathogen load. In all, IL-10 plays an indispensable role in mediating host anti-inflammatory 
response and hence identifying the cellular sources of IL-10. The molecular mechanisms 
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that regulate IL-10 expression are extremely important in developing therapeutic strategies 
directed against pathology-associated impaired IL-10 production [16].
IL-10 is considered to have multiple roles when it comes to immune regulation. It has been 
shown to inhibit production of many inflammatory molecules such as IL-12, MHC and other 
costimulatory molecules from dendritic cells and macrophages [17]. It is also shown to have 
role in B cell survival, proliferation and antibody production. More recently, its role in tumor 
immunity has been elucidated [18].
2.3. IL-10 as therapy
Owing to its unique properties, IL-10 is considered as a potential candidate for use in therapy 
against inflammatory diseases, chronic infections, cancer and autoimmunity. IL-10 is involved 
in feedback regulation of Th1 and Th2 responses. It has been reported that the levels of secre-
tion of Il-10 and IFN-γ through Th-1 is the deciding factor between clearance and persistence 
of infection. Studies in IL-10 deficient mice show that some intracellular pathogens could be 
cleared but is often accompanied by immunopathology. This clears the role of IL-10 in pre-
venting host damage and maintaining a balance [19].
IL-10 is widely tested as a therapeutic for inflammatory diseases. Administering recombinant 
IL-10 has been tested in many clinical trials for rheumatoid arthritis, Crohn’s disease and 
psoriasis [20]. All these clinical studies show the role of IL-10 in immune stimulatory as well 
as anti-inflammatory abilities. Because IL-10 has potential to prevent T cell-mediated tissue 
injury, it is often considered as a therapeutic for diseases involving autoimmune inflamma-
tion, the most studied model being autoimmune encephalomyelitis (EAE). The presence of 
IL-10 within the target organ is linked to its role in CNS inflammation and also in a null 
mouse model of acute CNS inflammation. The effectiveness of the therapy, however, depends 
upon the timing of IL-10 administration as well as target/route/localization because periph-
eral administration of IL-10 shows an exacerbated disease condition of EAE in mice [16, 19]. 
In case of various other infections, it is shown that a delicate balance of pro-inflammatory 
and anti-inflammatory environment is required for tackling the disease. Temporal and spatial 
IL-10 induction is critical for resolving any infection. Excessive IL-10 production can inhibit 
the pro-inflammatory response to a number of pathogens, including Leishmania spp., T. cruzi, 
Mycobacterium, Plasmodium spp., and Lymphocytic choriomeningitis virus, to the extent 
that pathogens can escape immune control, resulting in either persistent or chronic non-
treatable infections [21–23]. In cases of viral infections such as HIV and HCV, elevated IL-10 
signaling can inhibit pro-inflammatory cytokine production mainly via two processes, first 
is targeting of immune effector types directly, and second by indirectly modulating immune 
function eventually inhibiting maturation of different types of APCs such macrophage and 
dendritic cells, thus limiting co-stimulatory, chemokine secretion and antigen presentation 
capacity of the host. In the case of HIV, it has been reported that IL-10 hampers APC matura-
tion, limiting antigen presentation from these cells, and initiates T cell-dependent suppres-
sion of anti-viral responses [10, 24, 25].
We can thus say that IL-10 therapy can only be successful only if everything is just right 
from signaling to secretion. Dysregulation of IL-10 can lead to autoimmunity or severe 
immunopathology due to extended inflammation. Also there are pathogens that have 
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found ways to promote chronic establishment by hijacking the IL-10 regulation pathways. 
Hence IL-10 works differently in different environments, thus having a deeper knowledge 
of the intermediates involved in its functioning is necessary. Promising and most studied 
candidate seem to be type I interferons, IFN-γ as reviewed by many, but IL-12 can also act 
as a potential player.
Work from Cheng G. lab and others have shed light on the role of type I IFNs, IL-27, and 
IL-10 as suppressors of neurodegenerative diseases like EAE. Such diseases are induced as a 
result of impaired functioning of the immune system, wherein the system generates response 
against its own cells. These studies were important contributions highlighting potential effi-
cacy of IFNβ therapy against multiple sclerosis, which shares many of the clinical symptoms 
and features with EAE animal models. In case of viral infections, most pathology to the host is 
prevented via type I IFN. In case of acute respiratory influenza infection it is known that type 
I IFN exerts temporal control over excessive inflammation through the infiltration of IL-10-
producing lymphocytes at the infection site. However, type I IFN signaling is also known 
to worsen the pathology in context of chronic or persistent viral infections. Prolonged host-
derived IL-10 production can actively suppress pro-inflammatory T-cell responses, giving 
an opportunity to the virus to persist, as in case of LCMV infection. However, considerable 
success is achieved in re-establishment of T cell function by using molecules acting as IL-10 
antibody block. Theoretically elevated IL-10 expression could be initiated as well as sustained 
through type I IFN host response generated during the primary viral infection or initial phase 
of infection. Thus, type I IFN signaling could play double roles firstly by promoting robust 
clearance of acute viral infection via host directed anti-viral response, and secondly by creat-
ing an immunosuppressive environment that paves way for persistent or chronic infection to 
establish. IL-10 also modulates this excessively and hence understanding its potential from 
infection point of view is equally important.
3. IL-12
IL-12 is a pro-inflammatory cytokine that has been shown to enhance IFN-γ producing T cell 
responses and has been widely tested as a vaccine adjuvant. It is produced by phagocytes in 
response to microbial stimulation and is an important early mediator in host defense. IL-12 is 
known as a conjugate between innate and adaptive immunity as it induces IFN-γ production 
and thereby helps in polarizing naive CD4 T cells to become Th1 cells. Over and above this, 
IL-12 has also been shown to enhance CD8 T cell homeostasis and provide a third signal that 
promotes full activation and survival of activated CD8 T cells. Collectively, many studies have 
documented IL-12 as a potent inducer of effector T cells, and this property has led to its testing 
as commercial vaccine adjuvant.
3.1. IL-12 signaling
IL-12 is primarily produced by all professional APC types such as DC’s, monocytes and mac-
rophages. IL-12 is composed of two chains p-35 and p-40 encoded by IL-12a and IL-12b respec-
tively, activating NK cells and induce CD4 T cells to become IFN-γ producing Th1 type cells. 
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IFN-γ, in turn, acts on APCs to promote IL-12 secretion in a positive feedback loop. IL-12 sig-
nals via the IL-12 receptor (IL-12R) consisting of two subunits namely IL-12Rβ1 and IL-12Rβ2 
known to be expressed on DCs, T cells and NK cells. IL-12 functions via non-receptor Janus 
kinase 2 (JAK2) and tyrosine kinase 2 (TYK2) activities, leading to the phosphorylation of 
signal transducers and activators of transcription (STATs), mainly, STAT4 homodimers. IL-12 
is also involved in secretion of IL-2, TNF-α and GM-CSF apart from the main one IFN-γ.
3.2. Regulation of IL-12 production
Biologically active IL-12 is produced when both Il12a and Il12b genes are expressed coordi-
nately in the same cells. Contradictory to the notion, mRNA of Il12a is widely expressed in 
many cell types, albeit at low levels in some cells, most of which do not even produce IL-12. 
The Il12b mRNA is restricted to cells that can produce biologically active heterodimer. A 
rate-limiting step for IL-12 production is synthesis of the p35 chain linking to limited avail-
ability of its transcripts in cells under homeostatic conditions. Over the past 2 decades, a 
huge plethora of molecular analyses have identified numerous transcription factors that bind 
to the promoter regions of Il12a and Il12b. The promoters of Il12a have been shown to bind 
transcription factors such as nuclear factor kappa B (NFκB), c-Rel (in DCs), c-Maf, and IFN 
regulatory factor 1 (IRF-1) in activated macrophages. TLR signaling in DCs through LPS and 
other ligands is also reported as contributor in IL-12 production.
3.3. IL-12 in therapy
Owing to its pleotropic properties IL-12 is widely used in therapy against tumors and infec-
tions. Most effects of IL-12 are mediated via IFN-γ. IL-12 regulates inflammation via linking 
the innate and adaptive arms of the immune system (Figure 1a). It thus emerges as an early 
pro-inflammatory cytokine in immune response to pathogens. However, complete function-
ing requires signals from IFN-γ, CD40-CD40L interactions and IL-15 [26–29]. Role of IL-12 in 
tumor regression and chemotherapy is most studied. Many pre-clinical studies have dem-
onstrated the potent anti-tumor activity of IL-12. Extensive research is being carried out to 
deliver recombinant IL-12 directly to tumor site. The challenge here again is to understand at 
mechanistic level, the involvement of other pathways which could be immunosuppressive, 
administering IL-12 in a way which makes it less toxic, targeted tissue delivery and generat-
ing tailor made responses depending on the type of tumor.
To study the mechanism of protection of IL-12 in tumors, it is generally overexpressed in 
tumor cell lines. Subcutaneous inoculation of this cytokine in C26 colon carcinoma cells, B16 
melanoma cells and few others have shown to induce tumor suppression. In melanoma cells 
protection is mediated by ILCs (Innate Lymphoid Cells) and in colon carcinomas it is inde-
pendent of IFN-γ and rather dependent upon CD4 T cells and NK cells [30]. This sheds light 
on location dependence and also upon the role of various cell types involved in the process. 
Thus, the entire tumor microenvironment is affected by IL-12 in a variety of ways [31]. In B-16 
melanoma, IL-12 showed to remodel the vasculature by upregulating adhesion molecules 
having role in leucocyte migration to the tissue and also by inhibiting angiogenesis through 
IFN-γ secretion.
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Various genetically modified mice models have been used to explore the therapeutic poten-
tials of IL-12. It is well known that IL-12 therapy is dose and context dependent; hence vari-
ous routes of immunization have been tested in different localized tumor models. Delivery 
models used and studied include infusion of recombinant proteins, electroporation, gene 
therapy using non-viral and viral vectors, nanoparticles and microspheres containing IL-12 
and immune cells or non-immune cells expressing IL-12. IL-12 affects a series of events 
involved in tumor immunity. IL-12 acts on NK cells and CD8 T cells to trigger effector func-
tions via perforin and granzyme secretions. It also stimulates B cells to secrete anti-tumor 
antibodies. It acts upon CD4 T cells polarizing them to Th1 phenotype in turn secreting 
cytokines and IFN-γ. It in turn acts upon APCs promoting antigen and cross presentation 
enhancing cytotoxic activity. Owing to its activity, IL-12 is considered in combinational 
therapy with other cytokines, chemotherapeutic agents, peptide vaccines and monoclonal 
antibodies. This has also been tested in melanoma and mammary carcinoma models [32, 33]. 
Figure 1. (a) During acute infection settings, a pro-inflammatory environment is created mainly via secretion of IL-12 
through DC-T cell interaction, promoting Th1 responses which are IFN-γ promoting. APCs promote pathogen clearance 
and control by activating adequate effectors of adaptive immune system. On the other hand Th2 response is involved in 
B cell, mast cell activation under the influence of other cytokines. During late stages of infection, an anti-inflammatory 
environment is created by IL-10 secretion by Th1 & 2 cells, Tregs, NK cells and macrophages. (b) IL-10 and IL-12 both 
antagonize each other under different conditions such as tumor and auto-immunity suggesting a delicate balance 
between the two is necessary to prevent host from adverse effects.
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The main issue however with these therapies is excessive systemic IFN-γ production lead-
ing to toxicity. In combination to chemotherapy modest success was observed only if IL-12 
was administered at early stages. Hence the limitations lead to exploration of other modes 
of delivery and again based upon the type of tumor, suitable delivery methods need to 
be adapted. Several studies have evaluated the use of IL-12 for therapy by delivering this 
cytokine within the tumor site specifically. Even after most of these approaches resulted in 
impressive antitumor responses, the translation into the clinics was not satisfactory. There 
are many questions still remaining unanswered in the oncology field. Firstly, the schedule 
optimization for therapeutic IL-12 delivery in clinical trials has proved to be challenging. 
Various treatment schedules have been evaluated such as subcutaneous versus intravenous 
vs. intra-tumor in daily as well as consecutive injections. Even though the most successful 
way to administer IL-12 appeared to be in cycles of twice weekly injections, repeated admin-
istration of the cytokine leads to increased immunosuppressive properties of the tumor by 
the induction of IL-10 [34].
IL-12 also has major role in shaping immunological memory to viral infections. During a typi-
cal viral infection, T cells undergo via phases of T cell activation and differentiation, governed 
majorly by the cytokine micro-environment. IL-12 along with other cytokines such as IL-15 
assists in generating appropriate T cell responses. Of the two types of T cells, CD4 and CD8, 
the effects of type I IFNs and IL-12 on CD8 T cell differentiation are seen to be intersecting as 
they both directly provide signals to the responding cells. Also they act in co-ordination with 
antigenic and costimulatory signals thereby promoting the development as well as expansion 
of short-lived effector cells [35, 36]. These cell types are eliminated from the response once 
there job of limiting the pathogen is complete. The T cells which survive the entire process 
culminate into T cell memory. IL-12 signaling induces expression of T-box expressed in T cells 
(T-bet), a transcription factor which determines the differentiation state of the T cells. High 
levels of T-bet directly correlate with the terminal differentiation of short-lived effector T cells, 
while lower levels of T-bet are linked to the development of memory precursor T cells which 
can add up to the long-lived memory pool. It has been reported that CD8 T cells lacking the 
IL-12 receptor, IFN receptor (IFNAR), or both inflammatory cytokine receptors, are defective 
in the formation of short-lived cells following infection with LCMV, VSV, or the intracellular 
bacteria Listeria monocytogenes (LM) [37]. These receptor deficient CD8 T cells are known to 
express lower levels of T-bet and higher levels of Eomes, the related T-box transcription fac-
tor Eomesodermin. Although these transcription factors possess overlapping roles, in terms 
of initiating IFN-γ, the expression of Eomes is preferentially associated with the formation of 
memory CD8 T cells. Eomes may operate to recruit cells into the memory pool by upregulat-
ing expression of CD122, the b-chain of the IL-2 receptor, which is also required for IL-15 
signaling. Co-operation between cytokines shapes both short-term and long-lived anti-viral 
CD8 T cell development. Often the induction of type I IFN or IL-12 following infection boosts 
the expansion of highly cytolytic short-lived effector cells. Curtailing the inflammatory con-
ditions via investigating the exact roles of IL-10 surrounding CD8 T cells might permit the 
formation of long-lived memory populations attributing protection against re-exposure to the 
infection [38].
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4. Striking the IL-10/IL-12 balance for better therapeutic value
The potency of IL-12 and IL-10 in host defense makes them a target for precise regulation. 
Indeed, the temporal, spatial, and quantitative expression of these two cytokines during an 
immune response in a specific tissue microenvironment contributes to the determination of 
the type, extent, and resolution of the response in major ways. Disturbing the intricate control 
and balance frequently leads to immunologic disorders and pathologies. One of the most 
important and well-studied negative regulators of TLR-induced IL-12 production is IL-10. 
IL-10 repression of both IL12a and Il12b genes is primarily seen at the transcriptional level; 
however the inductions of the two genes have different requirements for de novo protein 
synthesis. IL-10 suppression Il12a transcription is not completely known. IL-10 acts upon 
the enhancer 10 kb upstream of the Il12b transcriptional start site, bound by nuclear factor, 
interleukin 3-regulated (NFIL3), which is a B-ZIP transcription factor. It has been reported 
that myeloid cells lacking NFIL3 produce excessive IL-12p40 and increased IL-12p70. This 
indicates that STAT3-dependent expression of NFIL3 is a key component of the negative feed-
back mechanism in myeloid cells that suppresses pro-inflammatory responses. Quite a bit 
of elegant studies have focused on the Il12b promoter transiently associated to acetylated 
histone H4 in WT bone marrow-derived macrophages (BMDMs), whereas association of 
these factors was seen to be prolonged in Il10−/− BMDMs. Experiments incorporating histone 
deacetylase (HDAC) inhibitors and HDAC3 short hairpin RNA have shown data to indi-
cate that HDAC3 is involved in histone deacetylation of the Il12b promoter by IL-10. This 
means the histone deacetylation on the Il12b promoter by HDAC3 mediates the homeostatic 
effect of IL-10 in macrophages. More details clearly need to be worked out to understand the 
important homeostatic regulation of IL-12 production by IL-10, in terms of cellular pathways, 
different mechanisms might be taking place in a tissue specific manner etc. In this context, 
the IL-4-inducing transcription factor c-Maf is an interesting molecule that can directly and 
conversely regulate IL-12 and IL-10 gene expression in activated macrophages. Again, IRF-5 
is considered as a factor leading to the “M1” polarization of macrophages thereby promoting 
Th1 and Th17 activities with activated transcription of inflammatory genes, including Il12a, 
Il12b, and Il23a, and repressed Il10 transcription [39].
A classic study by Lopez MV et al. showed the first evidence of synergistic anti-tumor effects 
of IL-12 and IL-10 in a novel combination cancer immunotherapy [40]. They demonstrated the 
eradication of established primary colon and mammary tumors by administering the Th1 and 
Th2 cytokine together. They observed an increased expression of IP-10, MCP-1 and TCA-3 at 
day 7 after administration of the combined immunotherapy. An interesting result was also 
the persistent expression of IFN-γ locally and the abrogation of IL-4 increase following the 
combined immunotherapy, indicating that infiltrating cells were expressing a Th1 phenotype. 
Simultaneous and timely activation of Th1 and Th2 responses is thus necessary for appropri-
ate responses.
Autoimmunity is a condition in which host generates immune responses against its own 
healthy cells. Experimental allergic encephalomyelitis (EAE), a demyelinating disease of 
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the central nervous system, is widely used as an animal model for multiple sclerosis. Segal 
et al., in 1988 demonstrate that IL-12 is essential for the generation of autoreactive Th1 cells 
that induce EAE, in the presence as well as absence of IFN-γ. The disease-promoting effects 
of IL-12 are often antagonized by IL-10 having its origin from antigen nonspecific CD4 T 
cell which, in turn, is regulated by the endogenous production of IL-12 (Figure 1b). This 
unique immune-regulatory circuit appears to play a non-ambiguous role in controlling Th 
cell differentiation. It also provides a mechanism through which microbial triggers of the 
innate immune system can harmonize autoimmune disease [41]. IL-12 has an EAE pro-
moting potential, it triggers formation of autoimmune effectors. Anti-IL-12 therapy helps 
in regression of disease through prolonged administration. The innate immune system 
would always trigger inflammatory responses towards autoimmune cells; a delayed IL-10 
secretion by a different subset of immune cells, the adaptive ones in turn suppresses the 
activity of autoimmune cells. This has been established in L. major and T. gondii mice infec-
tion models. This suggests that manipulating the cytokine milieu, balancing IL-12/IL-10 
ratio via the innate immune system can surmount establishment of autoimmune disorders. 
This may not hold true for chronic autoimmune diseases and more intervention is there-
fore required.
Generating CD8 T cell memory for infections due to intracellular pathogen has been an active 
area of research. IL-10 has been shown to promote resolution of infection, thereby promoting 
memory formation. The source of IL-10 is considered to be CD4 Tregs in acute LCMV model 
[42]. The probable reason for memory maturation of CD8 T cells could be their insulation to 
the pro-inflammatory effects of IL-12 driving them towards terminal effector differentiation. 
Pathogenic insult to the host triggers innate immune responses via NK cells and other innate 
immune cells. Microbial sensing occurs through PRRs (pattern recognition receptors) and the 
most studied of them being the TLRs (toll like receptors). TLR signaling pathway in turn leads 
to secretion of cytokines, pro-inflammatory ones, activating the adaptive arm. Innate immune 
cells together control the infection from spreading further. Upon activation of antigen specific 
T cells, a specific course follows which is dynamically in sync with increasing pathogen load. 
Upon clearing the pathogen, the antigen specific effector T cell population contracts to form 
a small pool of memory T cells. Several cytokines affect the phenomena of T cell maturation. 
The resolution phase has the role of IL-10 acting as anti-inflammatory and promoting T cell 
maturation which can add to the memory T cell pool. Thus this property of cytokines can be 
explored in vaccination strategies or designing new vaccine adjuvants. Therapeutic interven-
tion during specific stages of T cell maturation can help in generation of protective long lived 
immunological memory.
5. Conclusion
Maintaining homeostasis requires an intricate interplay among various functioning systems 
of the body (Figure 2). Cytokines form an important class of such system. Understanding the 
system properly and deeply would allow meaningful interventions and restoring the steady 
state.
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